Introduction {#s1}
============

Enteric (typhoid) fever, a systemic infection caused predominantly by the bacterium *Salmonella enterica* subspecies *enterica* serovar Typhi (*S*. Typhi), remains one of the principal bacterial causes of febrile disease in low-income countries ([@bib23]). *S*. Typhi is a distinct, monophyletic lineage of *S. enterica* that is exquisitely adapted to cause disease only in humans ([@bib26]), characterised by a non-specific fever with malaise and asymptomatic convalescent carriage ([@bib23]). There are an estimated 20--30 million new cases of enteric fever per year globally ([@bib5]), with the majority occurring in Asia, but there is an increasingly recognised burden of disease across sub-Saharan Africa.

Antimicrobial resistance is a major global health challenge, and resistance against the most commonly used antimicrobials for treating enteric fever has evolved successively over the last 30 years. Ampicillin, chloramphenicol and trimethoprim-sulfamethoxazole were originally standard-of-care for enteric fever. However, multidrug resistance (MDR) against these agents began to emerge in the 1970s and 1980s ([@bib20]; [@bib29]). Consequently, third-generation cephalosporins and fluoroquinolones (FQs) became the most clinically reliable drugs for treating enteric fever ([@bib12]), and were formally advocated by the World Health Organization (WHO) in 2003 ([@bib28]). *S*. Typhi isolates with acquired resistance against third-generation cephalosporins are rare ([@bib9]), but *S*. Typhi exhibiting reduced susceptibility to FQs, induced by sequential mutations in the gene encoding a target protein (*gyrA*), now dominate internationally ([@bib6]; [@bib13]). The global ascendency of *S*. Typhi strains with reduced susceptibility to FQs has been partly catalysed by the dissemination of a specific MDR lineage (H58) across Asia and Africa ([@bib30]). These H58 strains are rapidly displacing other lineages, and strains with *gyrA* mutations may have a fitness advantage, even in the absence of antimicrobial exposure ([@bib3]).

We have previously shown that protracted fever clearance times (FCTs) are associated with organisms with higher Minimum Inhibitory Concentrations (MIC) against FQs in enteric fever patients treated with ciprofloxacin and ofloxacin ([@bib25]). However, whilst the clinical efficacy of the older FQs in enteric fever is contentious, we have shown that the fourth-generation FQ, gatifloxacin, has remained efficacious for uncomplicated disease, even in patients infected with *S*. Typhi strains with reduced ciprofloxacin susceptibility (MIC ≥0.125 μg/mL) ([@bib21]; [@bib16]; [@bib1]).

During a recent randomised controlled trial (RCT) comparing ceftriaxone and gatifloxacin, conducted in Nepal, we observed an increased number of treatment failures associated with FQ-resistant (ciprofloxacin MIC\>32 μg/ml) *S*. Typhi, prompting the data safety and monitoring board to stop the trial ([@bib2]). Aiming to assess the molecular epidemiology of the infecting isolates and investigate how genotype may be related to treatment outcome, we performed whole genome sequencing (WGS) on the *S*. Typhi isolated during this trial, and after stratifying by genotype, we assessed clinical presentation and outcome.

Results {#s2}
=======

*Salmonella* Typhi whole genome sequencing {#s2-1}
------------------------------------------

We performed WGS on the 78 available *S*. Typhi isolates from patients in both RCT treatment arms (gatifloxacin and ceftriaxone) ([Supplementary file 1](#SD1-data){ref-type="supplementary-material"}). The resulting phylogeny, which incorporated reference sequence CT18, indicated that the majority of isolates (65/78; 83.3%) fell within the H58 lineage, while the remaining 13 (16.7%) represented eight different lineages ([Figure 1](#fig1){ref-type="fig"}). All but four of the H58 strains contained the common DNA gyrase (*gyrA*) mutation in codon 83 (S83F), which confers reduced susceptibility to FQs (ciprofloxacin MIC; 0.125--0 5 μg/ml) ([@bib24]). Nested within the S83F H58 group, but separated from the rest of the group by a branch defined by 30 SNPs, was an H58 subclade comprised of 12 isolates containing the S83F *gyrA* mutation, a mutation in *gyrA* at codon 87 (D87N), and an additional mutation in the topoisomerase gene, *parC* (S80I) (H58 triple mutant). Notably, these H58 triple mutants shared high MICs against ciprofloxacin (≥24 μg/ml). Further, an additional two non-H58 RCT isolates with ciprofloxacin MIC≥24 μg/ml had the S83F *gyrA* mutation, an alternative mutation at codon 87 (D87V), the S80I *parC* mutation, and an A364V mutation in *parE* ([Figure 1](#fig1){ref-type="fig"}, [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}). Notably, none of the sequenced isolates harboured plasmid-mediated quinolone resistance genes (PMQR) or contained additional antimicrobial resistance genes within the well-described *S*. Typhi-associated IncH1 family of plasmids.10.7554/eLife.14003.003Figure 1.The phylogenetic structure of 78 Nepali *Salmonella* Typhi isolated during a gatifloxacin versus ceftriaxone randomised controlled trial.Maximum likelihood phylogeny based on core-genome SNPs of 78 *Salmonella* Typhi RCT isolates with the corresponding metadata, including the presence of mutations (dark grey) in *gyrA* (S83F, D87V and D87N), *parC* (S80I) and *parC* (A364V) and susceptibility to ciprofloxacin (susceptible, light blue; intermediate, mid-blue and non-susceptible, dark blue) by Minimum Inhibitory Concentration (MIC). The reference strain CT18 was used for context and highlighted by the black boxes. Red lines linking to metadata show isolates belonging to the *Salmonella* Typhi H58 lineage (with H58 triple mutants highlighted), other lineages (non-H58) are shown with black lines. The scale bar indicates the number of substitutions per variable site (see methods). Asterisks indicate ≥85% bootstrap support at nodes of interest.**DOI:** [http://dx.doi.org/10.7554/eLife.14003.003](10.7554/eLife.14003.003)

Clinical presentation of *Salmonella* Typhi infections {#s2-2}
------------------------------------------------------

We stratified clinical data from the RCT by H58 status of the corresponding *S*. Typhi isolates (H58; N=65, non-H58; N=13) and compared baseline characteristics between these groups. We found no significant differences in demographics and no association between disease severity at presentation between those infected with an H58 *S*. Typhi isolate or a non-H58 isolate ([Supplementary file 2A](#SD2-data){ref-type="supplementary-material"}). Next, we compared the baseline characteristics of patients stratified by ciprofloxacin susceptibility (susceptible, intermediate and resistant), and found no differences in disease severity or demographics on presentation; the only exception being that FQ-resistant *S*. Typhi were more frequently isolated from adults ([Supplementary file 2B](#SD2-data){ref-type="supplementary-material"}). A significantly lower proportion of H58 *S*. Typhi (4/65; 6.2%) were susceptible to FQs compared to non-H58 isolates (6/13; 46%) (p=0.001) ([Table 1](#tbl1){ref-type="table"}) and, overall, H58 isolates had significantly higher (but not resistant) MICs against the majority of tested antimicrobials than non-H58 isolates ([Table 1](#tbl1){ref-type="table"}).10.7554/eLife.14003.004Table 1.Comparison of antimicrobial susceptibility by *Salmonella* Typhi lineage.**DOI:** [http://dx.doi.org/10.7554/eLife.14003.004](10.7554/eLife.14003.004)E testNon-H58 (N=13)H58 (N=65)p value\*MIC50MIC90GM (range)MIC50MIC90GM (range)Amoxicillin0.510.77 (0.38--38)0.75\>2561.43 (0.38--\>256)0.0412Chloramphenicol342.7 (1.5--8)4125.7 (2--\>256)0.0147Ceftriaxone0.060.060.06 (0.05--0.13)0.090.190.11 (0.03--0.64)0.0004Gatifloxacin0.130.250.06 (0.01--2)0.1320.21 (0.01--3)0.1197Nalidixic acid\>256\>25621.6 (1--\>256)\>256\>256346.8 (1--\>256)0.0004Ofloxacin0.250.750.24 (0.03--\>32)0.5\>32321.09 (0.03--\>32)0.0240Trimethoprim sulphate0.020.050.03 (0.02--0.05)0.050.320.09 (0.01--\>32)0.0016Ciprofloxacin0.130.750.11 (0.01--\>32)0.38\>320.80 (0.02--\>32)0.0051Ciprofloxacin susceptibility group0.0008^\#^- Susceptible6 (46.2%)4 (6.2%)- Intermediate4 (30.8%)48 (73.8%)- Resistant3 (23.1%)13 (20.0%)[^1][^2][^3][^4]

Treatment failure and fever clearance times {#s2-3}
-------------------------------------------

The primary endpoint of the RCT in which these data were generated was a composite for treatment failure (see method and previous publication) ([@bib2]). Treatment failure with H58 *S*. Typhi was significantly less common in the ceftriaxone group (3/31; 9.7%) than the gatifloxacin group (15/34; 44.1%) (Hazard Ratio (HR) of time to failure 0.19, 95%CI 0.05--0.56, p=0.002) ([Table 2](#tbl2){ref-type="table"}). Conversely, there was no significant difference in treatment failure between those infected with non-H58 isolates treated with gatifloxacin (0/6; 0%) or ceftriaxone (2/7; 28.6%) (p=0.32). Similarly, time to fever clearance differed significantly between the two treatment groups in H58 infections, with median FCTs of 5.03 days (interquartile range (IQR): 3.18--7.21) in the gatifloxacin group and 3.07 days (IQR: 1.89--4.52) in the ceftriaxone group (p\<0.0006). Again, this trend was not mirrored in the non-H58 *S*. Typhi infections, with FCTs of 2.87 (IQR: 2.08--3.7) and 3.12 (IQR: 2.2--4.12) days for gatifloxacin and ceftriaxone, respectively (p=0.61) ([Table 3](#tbl3){ref-type="table"}). Moreover, in the gatifloxacin arm, H58 *S*. Typhi tended to be associated with a higher risk of treatment failure (p=0.06) and a longer fever clearance time (p=0.013) ([Figure 2](#fig2){ref-type="fig"}, [Table 2](#tbl2){ref-type="table"} and [Supplementary file 2C](#SD2-data){ref-type="supplementary-material"}).10.7554/eLife.14003.005Table 2.Summary of time to treatment failure by *Salmonella* Typhi lineage and ciprofloxacin susceptibility.**DOI:** [http://dx.doi.org/10.7554/eLife.14003.005](10.7554/eLife.14003.005)Time to treatment failureGatifloxacin (events/N)Ceftriaxone (events/N)Hazard ratio of time to failure (95%CI); p valueHeterogeneity test\
(p value)H58\*0.020- H5815/343/310.19 (0.05, 0.56); p=0.002- Non-H580/62/73.87 (0.31, 534.24); p=0.32Ciprofloxacin susceptibility group^†^0.08- Susceptible0/51/52.40 (0.13, 350.21); p=0.57- Intermediate7/252/270.27 (0.05, 0.99); p=0.049- Resistant8/102/60.27 (0.05, 1.01); p=0.052[^5][^6]10.7554/eLife.14003.006Figure 2.The association of *Salmonella* Typhi lineage and ciprofloxacin susceptibility with treatment failure and fever clearance time in patients randomised to gatifloxacin.(**A**) Kaplan-Meier curve for time to treatment failure by H58 and non-H58 *Salmonella* Typhi. (**B**) Kaplan-Meier curve for time to treatment failure by *Salmonella* Typhi susceptibility group (susceptible, intermediate, resistant to ciprofloxacin). (**C**) Non-parametric maximum likelihood estimators for interval-censored fever clearance time (see methods) by H58 and non-H58 *Salmonella* Typhi. (**D**) Non-parametric maximum likelihood estimators for interval-censored fever clearance time by *Salmonella* Typhi susceptibility group (susceptible, intermediate, resistant to ciprofloxacin).**DOI:** [http://dx.doi.org/10.7554/eLife.14003.006](10.7554/eLife.14003.006)

As we identified two non-H58 isolates that were also FQ-resistant ([Figure 1](#fig1){ref-type="fig"}), we additionally stratified outcome for the gatifloxacin arm (N=40 patients) by FQ susceptibility of the infecting organism. Those infected with FQ-resistant *S*. Typhi failed gatifloxacin treatment more frequently (8/10; 80%) than those infected with an intermediately resistant organism (7/25; 28%) or a susceptible organism (0/5; 0%) (p=0.007) ([Figure 2](#fig2){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"}). Furthermore, in the gatifloxacin arm, those infected with FQ-resistant organisms had significantly higher median FCTs than those infected with *S.* Typhi with alternative FQ susceptibility profiles (median FCTs (days): susceptible, 2.96 (IQR: 2.13--3.85), intermediate, 4.01 (IQR: 2.76--5.37) and resistant 8.2 (IQR: 5.99--10.5), respectively \[p\<0.0001\]) ([Table 3](#tbl3){ref-type="table"} and [Supplementary file 2D](#SD2-data){ref-type="supplementary-material"}). Comparatively, the median FCT for those infected with an FQ-resistant organism but randomised to ceftriaxone was 3.83 days (IQR: 2.96--4.7) (p\<0.0001 for the between-treatment comparison).10.7554/eLife.14003.007Table 3.Summary of fever clearance time by Salmonella Typhi lineage and ciprofloxacin susceptibility.**DOI:** [http://dx.doi.org/10.7554/eLife.14003.007](10.7554/eLife.14003.007)Fever clearance timeGatifloxacin median (IQR) daysCeftriaxone median (IQR) daysAcceleration factor (95%CI); p valueHeterogeneity test\
(p value)H58^¥^0.07- H585.03 (3.18, 7.21)3.07 (1.89 ,4.52)1.59 (1.22, 2.09); p=0.0006- Non-H582.87 (2.08, 3.7)*3*.12 (2.2, 4.12)0.90 (0.59, 1.36); p=0.61Ciprofloxacin susceptibility group^‡^0.015- Susceptible2.96 (2.13, 3.85)4.78 (4.01, 5.5)0.71 (0.49, 1.02); p=0.07- Intermediate4.01 (2.76, 5.37)2.63 (1.52, 4.05)1.31 (0.97, 1.76); p=0.07- Resistant8.2 (5.99, 10.5)3.83 (2.96, 4.7)2.23 (1.57, 3.17); p\<0.0001[^7][^8]

The emergence of fluoroquinolone-resistant *Salmonella* Typhi {#s2-4}
-------------------------------------------------------------

To measure the pattern of emergence of FQ-resistant *S*. Typhi in Nepal, we compiled FQ susceptibility data from 837 organisms isolated during enteric fever RCTs conducted at Patan Hospital between 2005 and 2014 ([Figure 3](#fig3){ref-type="fig"}) ([@bib21]; [@bib16]; [@bib1]). MICs against FQs were generally higher for *S*. Paratyphi A than for *S*. Typhi. There was a significant temporal increase in *S*. Typhi MICs against both ciprofloxacin (p\<0.0001) and gatifloxacin (p\<0.0001), with a sharp increase from 2009. MICs against gatifloxacin in *S.* Paratyphi A also significantly increased with time (p\<0.0001); however, MICs against ciprofloxacin showed only weak evidence of an upward trend over time (p=0.06).10.7554/eLife.14003.008Figure 3.Minimum Inhibitory Concentrations of Nepali *Salmonella* Typhi and *Salmonella* Paratyphi against ciprofloxacin and gatifloxacin over ten years.Minimum Inhibitory Concentrations (μg/ml) for 568 Nepali *Salmonella* Typhi (blue) and 269 Nepali *Salmonella* Paratyphi A (grey) against (**A**) ciprofloxacin and (**B**) gatifloxacin collected from four randomised controlled trials conducted between 2005--2014 at Patan Hospital in Kathmandu, Nepal ([@bib21]; [@bib16]; [@bib1]). The smoothed line derived from the generalized additive model showing a non-linear increase in Minimum Inhibitory Concentrations over time, with shading representing the 95% confidence interval. Lower and upper horizontal lines represent the current CLSI cut-offs for susceptible/intermediate and intermediate/resistant, respectively ([@bib4]).**DOI:** [http://dx.doi.org/10.7554/eLife.14003.008](10.7554/eLife.14003.008)

We hypothesised that the H58 triple mutants represented a contemporary importation into Nepal. To explore this, we compared the genomes of the 78 RCT *S*. Typhi isolates with those from 58 supplementary *S*. Typhi isolates from previous studies conducted between 2008 and 2013 in this setting ([Figure 4](#fig4){ref-type="fig"}, [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}) ([@bib30]). We found that the majority of the local H58 isolates (84/121; 69.4%) were closely related; these strains represented an \'endemic\' Nepali H58 clade containing a single S83F *gyrA* mutation. Additionally, we identified a further five Nepali strains isolated in 2013 that belonged to the H58 triple mutant group, and had an MIC ≥24 μg/ml against ciprofloxacin. Incorporating additional genome sequences from a recent international study of the H58 lineage ([@bib30]), we found that all the Nepali H58 triple mutants were very closely related (5 SNPs to nearest neighbour) to H58 triple mutants isolated previously in neighbouring India between 2008 and 2012 ([Figure 4](#fig4){ref-type="fig"}).10.7554/eLife.14003.009Figure 4.The phylogenetic structure of fluoroquinolone resistant *Salmonella *Typhi in a regional context.Maximum likelihood phylogeny based on core-genome SNPs of 136 (78 from the RCT) *Salmonella* Typhi isolates from Nepal and neighbouring India ([Supplementary file 1](#SD1-data){ref-type="supplementary-material"}). Main tree shows the overall phylogenetic structure and the presence of specific combinations of mutations in *gyrA* (S83F, D87V and D87N), *parC* (S80I) and *parE* (A364V). The inset shows a magnified view of the fluoroquinolone-resistant *Salmonella* Typhi H58 triple mutants from Nepal and their close association with similarly fluoroquinolone-resistant *Salmonella* Typhi H58 triple mutants from India ([@bib30]). The scale bar on the primary tree indicates the number of substitutions per variable site, while that in the inset indicates genetic distance in number of SNPs (see methods). Asterisks indicate ≥85% bootstrap support at nodes of interest.**DOI:** [http://dx.doi.org/10.7554/eLife.14003.009](10.7554/eLife.14003.009)

Discussion {#s3}
==========

Our study shows that a new FQ-resistant subclade of H58 *S*. Typhi has been introduced into Nepal and is associated with a lack of FQ efficacy. This subclade was associated with longer FCTs and treatment failure in patients treated with the FQ, gatifloxacin. For the first time, we can conclusively show how enteric fever patients respond to FQ treatment when infected with a specific subclade of H58, thereby linking organism genotype with a treatment phenotype. Given the international significance of FQs for the treatment of enteric fever and other bacterial infections, our findings have major global health implications for the long-term use and efficacy of this group of antimicrobials.

Our data suggest these FQ-resistant *S*. Typhi strains circulating in Nepal most likely descended from a single ancestor carrying the triple *gyrA/parC* mutant, such as that isolated in Nepal in 2011 ([@bib15]). This isolate was also associated with treatment failure, although this organism was not genome sequenced and was assumed to be an isolated case. More significantly, several very closely related strains were genome sequenced during an international study of H58 *S*. Typhi ([@bib30]). These organisms had the same combination of triple FQ resistance mutations as those described here; our analysis shows they belong to the same subclade of H58. These strains had equivalently high MICs against ciprofloxacin and were isolated in India between 2008 and 2012. However, there were no associated patient outcome data for these strains and other reports from India have been limited. Our data implies that this lineage was introduced into Nepal from India or elsewhere in South Asia within the last 4--5 years and has subsequently entered in an endemic transmission cycle in Kathmandu. Given the large extent of human movement between India and Nepal, we propose this is the most likely route of introduction. However, there is also a small possibility that multiple strains independently gained resistance against FQs through the same selective pressure.

Appropriate antimicrobial therapy is critical in the treatment of enteric fever, as effective drugs curtail symptoms and prevent life threatening complications. Our data has substantial repercussions for enteric fever treatment, and we advocate that FQs should no longer be used for empirical enteric fever therapy on the Indian subcontinent, as we predict these strains are likely to be widespread and are associated with poor outcomes with FQ therapy. Notably, in the RCT from which these data were derived we used the newer generation FQ, gatifloxacin, which binds to a different location on the DNA gyrase than the older FQs and is not as susceptible to the common resistance mutations ([@bib19]). The isolates in this study were not generally resistant to gatifloxacin according to the current CLSI guidelines for Enterobacteriaceae ([@bib4]); we suggest that these guidelines be modified specifically for *S*. Typhi to reflect these new clinical data. We additionally propose that *S*. Typhi genotyping, mapping and susceptibility testing is performed routinely and rapidly in reference laboratories inside and outside of South Asia to monitor the international spread of these strains and ensure the provision of alternative efficacious therapies to returning travellers ([@bib17]; [@bib8]). In cases of infection with these FQ-resistant isolates, we suggest that ceftriaxone and azithromycin be used as alternatives, and do not currently recommend a return to the use of first-line drugs without contemporary data on treatment outcome. Whilst none of the isolates in this study were MDR, we predict a rapid return of MDR strains if there is a hasty return to older first-line alternatives.

This study has limitations. First, the clinical data was collected from one study in a single location, thus limiting utility outside this setting. Second, the overall sample size (and the gatifloxacin group subsampling) of those with culture-positive *S*. Typhi-associated enteric fever was relatively small, and the analysis presented here was performed in a *post hoc* manner. Notwithstanding these limitations, we were able to show a highly significant association between disease outcome and susceptibility profile of the infecting organism. Further, by using WGS, we were able to pinpoint causative mutations, identify the subclade responsible for treatment failure and relate these strains to other isolates circulating outside Nepal in other parts of South Asia. The methodologies presented here, in which clinical outcome data are combined with genome sequences and antimicrobial susceptibility data, should become the gold standard for informing empiric treatment for all invasive bacterial infections and understanding the role of bacterial genotype and resistance profile on disease outcome for other bacterial infections. No other combination of methodologies would provide the granularity of data required to understand the epidemiology and clinical impact of this emergent strain in detail.

In conclusion, our data, for the first time, show a significant association between *S*. Typhi genotype, antimicrobial susceptibility and disease outcome for those treated with gatifloxacin in a cohort of Nepali enteric fever patients. A FQ-resistant variant of Typhi H58 has emerged in Nepal and is associated with the clinical failure of FQs. Our data suggest these isolates are likely widespread in the subcontinent and FQs should not be recommended for empirical enteric fever therapy in this setting.

Materials and methods {#s4}
=====================

Study design and setting {#s4-1}
------------------------

The RCT from which the organisms and corresponding clinical data originated for these analyses was conducted at Patan Hospital and the Civil Hospital in the Lalitpur area of Kathmandu, Nepal, between 2011 and 2014, as described previously ([@bib2]). The trial was registered at [www.clinicaltrials.gov](www.clinicaltrials.gov) (ISRCTN63006567). Briefly, patients were randomly assigned to seven days of treatment with either oral gatifloxacin (400 mg tablets, Square Pharmaceuticals Limited, Bangladesh) at a dose of 10 mg/kg once daily or intravenous ceftriaxone (Powercef, 1000mg injection vial, Wockhardt Ltd, India), injected over 10 min at a dose of 60 mg/kg up to a maximum of two grams (aged 2 to 13 years) or two grams (≥14 years) once daily.

A detailed description of the RCT from which these data were generated has been previously published ([@bib2]). The primary endpoint was a composite of treatment failure, defined as the occurrence of at least one of the following events: fever clearance time (FCT) (time from the first dose of a study drug until the temperature dropped to ≤37·5°C and remained there for at least two days) more than seven days post-treatment initiation; requirement for rescue treatment as judged by the treating physician; blood culture positivity for *S.* Typhi or *S.* Paratyphi on day eight of treatment (microbiological failure); culture-confirmed or syndromic enteric fever relapse within 28 days of initiation of treatment; and the development of any enteric fever-related complication (e.g. clinically significant bleeding, fall in the Glasgow Coma Score, perforation of the gastrointestinal tract and hospital admission) within 28 days after the initiation of treatment. Time to treatment failure was defined as the time from the first dose of treatment until the date of the earliest failure event. FCTs were calculated electronically using twice-daily recorded temperatures and treated as interval-censored outcomes. Patients without fever clearance or relapse, respectively, were censored at the time of their last follow-up visit (additional details regarding study procedures can be found in Arjyal *at al*. 2016 ([@bib2])).

Blood (3 ml if aged \<14 years; 8 ml if aged ≥14 years) was taken from all patients for bacterial culture on enrolment. Adult blood samples were inoculated into media containing tryptone soya broth and sodium polyanethol sulphonate, up to a total volume of 50 mL. Bactec Peds Plus culture bottles (Becton Dickinson, New Jersey, USA) were used for paediatric blood samples. Culture results were reported for up to seven days, positive bottles were subcultured onto blood, chocolate and MacConkey agar and presumptive *Salmonella* colonies were identified using standard biochemical tests and serotype-specific antisera (Murex Biotech, Dartford, England). Antimicrobial susceptibility testing was performed by the modified Bauer-Kirby disc diffusion method with zone size interpretation based on CLSI guidelines ([@bib4]). Etests were used to determine MICs, following the manufacturer\'s recommendations (bioMérieux, France). Ciprofloxacin MICs were used to categorise *S*. Typhi isolates as susceptible (≤0.06 μg/mL), intermediate (0.12--0.5 μg/mL) and resistant (≥1 μg/mL) following CLSI guidelines ([@bib4]).

Whole genome sequencing and analysis {#s4-2}
------------------------------------

Genomic DNA from Nepali *S.* Typhi organisms originating from this RCT (78 isolates) was extracted using the Wizard Genomic DNA Extraction Kit (Promega, Wisconsin, USA) ([Supplementary file 1](#SD1-data){ref-type="supplementary-material"}) ([@bib14]). Two μg of genomic DNA was subjected to WGS on an Illumina Miseq platform, following the manufacturer's recommendations to generate 250bp/100bp paired-end reads. All reads were mapped to the reference sequence of *S.* Typhi CT18 (accession no: AL515582) using SMALT (version 0.7.4). Candidate single nucleotide polymorphisms (SNPs) were called against the reference sequence using SAMtools ([@bib18]) and filtered with a minimal phred quality of 30 and a quality cut-off of 0.75. The allele at each locus in each isolate was determined by reference to the consensus base in that genome, using *samtools mpileup* and removing low confidence alleles with consensus base quality ≤20, read depth ≤5 or a heterozygous base call. SNPs called in phage regions, repetitive sequences or recombinant regions were excluded, ([@bib30]) resulting in a final set of 1,607 chromosomal SNPs. Strains belonging to haplotype H58 were defined by the SNP *glpA*-C1047T (position 2348902 in *S*. Typhi CT18, BiP33) ([@bib6]; [@bib10]; [@bib22]).

A maximum likelihood (ML) phylogeny was estimated using a 1440 SNP alignment of the 78 RCT isolates in RAxML (version 7.8.6) with the generalized time-reversible substitution model (GTR) and a gamma distribution, with support for the phylogeny assessed via 1000 bootstrap replicates. The alignment was then compared to a global *S.* Typhi sequence database, with a particular focus on identifying sequences with a mutational profile suggestive of shared ancestry with a divergent H58 clade identified in the previous phylogeny. A secondary ML phylogenetic tree was then inferred from the SNP alignment of the 136 Nepali Typhi along with 19 recently described Typhi H58 with the aforementioned mutational profile, using the same parameters as above (1642 SNPs; [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}) ([@bib30]). Raw sequence data are available in the European Nucleotide Archive (ENA) ([Supplementary file 1](#SD1-data){ref-type="supplementary-material"}).

Statistical analysis {#s4-3}
--------------------

Comparison of baseline characteristics within patient groups, stratified by the H58 status or susceptibility category of their corresponding *S*. Typhi isolates was performed using the Kruskal Wallis test for continuous variables and Fisher's exact test for categorical variables. Time to treatment failure was analysed using Firth's penalized maximum likelihood bias reduction method for Cox regression as a solution for the non-convergence of likelihood function in the case of zero event counts in subgroups ([@bib7]). For comparisons between treatment arms, H58 status, or ciprofloxacin susceptibility group, the model included treatment arm, H58 status, or susceptibility group as a single covariate. Confidence intervals (CI) and *p*-values were calculated by profile-penalized likelihood. FCT was analysed as an interval-censored outcome, i.e. as the time interval from the last febrile temperature assessment until the first afebrile assessment, using parametric Weibull accelerated failure time models ([@bib11]). Median and inter-quartile range (IQR) FCT calculations for subgroups were based on models for each subgroup separately. Acceleration factors were based on models that included treatment arm as the only covariate. The non-parametric maximum likelihood estimator (NPMLE) was used to visualize the distribution of FCT between groups. Heterogeneity between subgroups was tested with models that included an interaction between treatment arm and the sub-grouping variable. To study the emergence of FQ resistance, data from previous enteric fever trials from 2005--2014 ([@bib21]; [@bib16]; [@bib1]) was pooled and generalized additive models (GAM) were used to examine potential non-linear trends of ciprofloxacin and gatifloxacin MICs over time. All analyses were performed using R software version 3.2.2 ([@bib27]).
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###### Table of *Salmonella* Typhi isolates and their corresponding sequencing metadata used in this study.

**DOI:** [http://dx.doi.org/10.7554/eLife.14003.010](10.7554/eLife.14003.010)
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###### (A) Table of baseline characteristics by *Salmonella* Typhi lineage.

\(B\) Table of baseline characteristics grouped by *Salmonella* Typhi ciprofloxacin susceptibility. (C) Table of treatment failure in detail by *Salmonella* Typhi lineage in the gatifloxacin treatment group. (D) Table of treatment failure in detail by ciprofloxacin susceptibility in the gatifloxacin treatment group.

**DOI:** [http://dx.doi.org/10.7554/eLife.14003.011](10.7554/eLife.14003.011)
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Duy Pham Thanh, Stephen Baker, Kathryn E Holt, Gordon Dougan, Vanessa Wong,2015,Sequence data,<http://www.ebi.ac.uk/ena/data/view/PRJEB10959>,PRJEB10959
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Decision letter

Jha

Prabhat

Reviewing editor

Saint Michael\'s Hospital

,

Canada

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"A novel ciprofloxacin-resistant subclade of H58 *Salmonella Typhi* is associated with fluoroquinolone treatment failure\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom, Brent House, has agreed to reveal his identity, and the evaluation has been overseen by Prabhat Jha as the Reviewing and Senior Editor.

The reviewers have discussed the reviews with one another and the editor has drafted this decision to help you prepare a revised submission.

Summary:

We believe this is a strong paper that could be published in *eLife*. To do so we request that you consider one (reasonably minor) revision and address also some minor points.

Please address these points in a revised manuscript with a point-by-point reply to the key revisions/minor points for us to consider further.

Essential revisions:

One weakness we observed with the article is that there is a huge amount of information from the clinical trial (Arjyal et al.et al., 2016) that is repeated in the Methods section, subheading "Study design and setting", and this appears rather redundant.

*Reviewer \#1:*

Considering the limitations, this research project was well designed and the manuscript well written. I believe the statistical analyses, Discussion and Conclusion were all accurate and reasonable.

*Reviewer \#2:*

This is a very well written article with profound outcomes for the management of typhoid fever in South East Asia and other regions where resistance to fluoroquinolones has emerged as a major concern.

The detection of *S. Typhi* isolates within H58 subclade that have triple mutations in the QRDR is a major finding that explains the apparent treatment failure observed in the recently concluded clinical trial quoted by authors (Arjyal et al., 2016) and earlier in studies in India, and this will inform clinical management where similar strains are isolated in the region and elsewhere.

One weakness I observed with the article is that there is a huge amount of information from the clinical trial (Arjyal et al., 2016), that is repeated in the Methods section, subheading "Study design and setting" and this appears rather redundant.

*Reviewer \#3:*

This is a well written and, I believe, significant report. It grows out of a large clinical trial performed in the Kathmandu Valley in Nepal that was comparing gatifloxacin with ceftriaxone in the treatment of individuals with enteric (typhoid) fever.

During the study period, there was emergence of a highly resistant strain of *Salmonella typhi*, the cause of typhoid fever (requiring the DSMB to halt the study because of the high failure rate). The researchers were thus in a unique situation. They had detailed clinical information, as well as the isolates, and were able to perform whole genome sequencing of the collected strains. They were then able to perform a detailed phylogenetic analysis, correlating that with the clinical information, specifically fourth generation fluoroquinolone failure. The main finding of the study is that the authors identified a subclade of the H58 lineage that had not only the DNA (*gyrA*) S83F mutation, but two additional mutations D87N (*gyrA*) and S80I in topoisomerase *parC*. The subclade that had triple mutations was associated with much higher MICs to ciprofloxacin, decreased fever clearance time, and clinical failure. They compared this subclade to a repository and identified relationships with isolates circulating in India prior to the time of the study. They hypothesize that the subclade was introduced into Nepal from India and is spreading.

I believe the work is significant for a number of reasons. It is to the best of my knowledge one of the most detailed studies correlating whole genome analysis to clinical outcome in the typhoid field (a human-restricted infection of high global importance; since it is human-restricted among impoverished people in resource-limited areas, it is notoriously hard to investigate), especially pertaining to the specific development and evolution of drug resistance over time. The work is not only scientifically informative but clinically extremely useful. The authors are correct that their results strongly suggest that even advanced fluoroquinolone antibiotics can no longer be used for the treatment of individuals with typhoid fever in the Indian subcontinent, and that this subclade may rapidly spread globally (the H58 clade has globally spread very rapidly, replacing previous clades, and appears to have a fitness advantage). The removal of fluoroquinolones from the therapeutic armamentarium cannot be overstated. It is the life blood of treating patients with typhoid (oral, cheap, effective). But the emergence of this H58 subclade now removes FQ as a weapon class in South Asia (and probably shortly globally given the H58 provenance); requiring either falling back on intravenous agents (not practical/optimal/feasible for many patients with typhoid) or azithromycin, the last oral chess piece on the table. It is in part due to this context, that I believe the work has additional unique global significance.

I have no major concerns with the manuscript.

10.7554/eLife.14003.015

Author response

*Essential revisions:*

One weakness we observed with the article is that there is a huge amount of information from the clinical trial (Arjyal et al.et al., 2016) that is repeated in the Methods section, subheading "Study design and setting", and this appears rather redundant.

Yes we agree and this required to be added at an earlier stage, we have referenced the majority of this but left in the important study design features to ensure the paper can be read without reference to the RCT.

[^1]: \*Comparisons between *Salmonella* Typhi lineage for MICs and ciprofloxacin susceptibility groups were based on the Wilcoxon rank sum test and Fisher's exact test. respectively.

[^2]: MIC: minimum inhibitory concentration, measured in µg/ml.

[^3]: \#p value for comparison of susceptible vs. intermediate/resistant combined between groups by Fisher's exact test is 0.001.

[^4]: GM: geometric mean, the upper range of the values was determined by multiplying the MIC by 2 if the result was \>X (for example, \>256 = 256\*2 = 512).

[^5]: \*Likelihood ratio test p=0.06 and 0.40 for comparison of time to treatment failure between H58 vs. non-H58 groups in gatifloxacin arm only and in all patients, respectively.

[^6]: ^†^Likelihood ratio test p=0.007 for comparison of time to treatment failure between MIC groups in gatifloxacin arm only.

[^7]: ^¥^p=0.013 and p=0.029 for comparison of interval censored time to fever clearance between H58 vs. non-H58 groups in gatifloxacin arm only and in all patients, respectively.

[^8]: ^‡^p\<0.0001 for comparison of interval censored time to fever clearance between MIC groups in gatifloxacin arm only.
